Propanc Biopharma Compares PRP to Erasca’s ERAS-0015 in Pancreatic Cancer Treatment

MELBOURNE, Australia, Sept. 22, 2026 /CourierPR/ -- Propanc Biopharma, Inc., a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, has released a comparative analysis of its lead candidate PRP against Erasca, Inc.’s pan-RAS molecular glue ERAS-0015 in the treatment of pancreatic ductal adenocarcinoma (PDAC). The analysis follows the FDA approval of Revolution Medicines’ daraxonrasib in pretreated metastatic PDAC in August 2026 and the FDA Fast Track designation for ERAS-0015 in metastatic pancreatic adenocarcinoma on August 24, 2026.

PRP, a proprietary fixed-ratio combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen (1:6), does not inhibit RAS. Instead, it promotes differentiation of malignant cells toward a more normal phenotype, reverses epithelial-mesenchymal transition (EMT), depletes cancer stem cells (CSCs), and remodels the fibrotic tumor microenvironment (TME). Propanc believes this non-cytotoxic, differentiation-based approach is complementary to RAS inhibitors and pan-RAS molecular glues like ERAS-0015.

In preclinical studies, PRP achieved significant tumor-growth inhibition and survival benefits in advanced PDAC models. Specifically, three-times-weekly intravenous PRP achieved greater than 90% mean tumor-growth inhibition compared to vehicle controls (p < 0.001). The treatment also resulted in a marked reduction in metastatic burden in the liver and peritoneum. Additionally, PRP significantly remodeled the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of EMT markers. The treatment also enhanced the sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting the potential for lower chemotherapy doses with improved efficacy. Median overall survival extension was more than 2.5-fold in treated animals compared to controls.

These results complement previously reported >85% tumor-growth inhibition data and peer-reviewed findings on PRP’s effects on PDAC fibroblasts. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients, with a favorable safety profile and no severe treatment-related adverse events.

PRP holds FDA Orphan Drug Designation for pancreatic cancer and is not restricted to a specific RAS genotype, supporting potential broad applicability across solid tumors and possible use in combination or sequential settings with RAS inhibitors or standard chemotherapy.

According to Erasca’s public disclosures, ERAS-0015 is an oral pan-RAS molecular glue designed to inhibit RAS signaling, including signaling driven by mutant RAS. Preliminary Phase 1 monotherapy data from the U.S. AURORAS-1 trial and the China JYP0015M101 study have shown unconfirmed overall response rates (uORR) of 40% at pharmacologically active doses of 16-32 mg once daily and 42% at recommended expansion doses of 24-32 mg in second-line KRAS G12X PDAC. A July 2026 update reported a 57% unconfirmed 8-week ORR at the 32 mg once-daily recommended expansion dose in second-line or later KRAS G12X PDAC. Responding patients remained on treatment as of May 25, 2026, data cutoff. The treatment generally showed favorable early tolerability, with mostly low-grade treatment-related adverse events, no dose-limiting toxicities at disclosed cutoffs, and 100% median relative dose intensity at 24 mg and 32 mg once daily.

The company is accelerating its Phase 1b First-in-Human study in advanced solid tumors, with pancreatic cancer as a key focus indication. The multicenter, open-label study is expected to enroll approximately 40 to 50 patients with advanced solid tumors, including pancreatic, ovarian, and other refractory cancers, with first patient dosing targeted for February 2027. A clinical trial application is expected in the coming months.

Propanc Biopharma remains committed to developing innovative treatments for chronic diseases, including recurrent and metastatic cancer, with a focus on addressing the underlying drivers of cancer proliferation and spread.